The HL7 CodeX FHIR® Accelerator continues to demonstrate how interoperability can move from concept to execution. Through a structured, use case-driven approach and alignment across providers, technology vendors, and life sciences organizations, CodeX is enabling standardized data exchange that improves efficiency, reduces administrative burden, and supports timelier, data-driven care.
This progress is increasingly visible across the industry. At the HIMSS Global Health Conference in March of this year, CodeX highlighted its work in genomics and data liquidity, emphasizing a critical shift in how interoperability is being defined. The focus is no longer limited to enabling data exchange, but rather ensuring that data can be consistently accessed, shared, and reused across clinical care, research, and public health. By grounding this vision in real-world implementations of FHIR and mCODE, CodeX demonstrated how standardized approaches to genomic data are beginning to scale, unlocking greater value in precision medicine and reinforcing the importance of aligning standards with practical workflows.
Across its portfolio, CodeX continues to make measurable progress through high-impact use cases. The completion of the Clinical Trials use case marks a significant milestone, demonstrating how standardized data can better connect clinical care and research by improving trial matching, accelerating recruitment, and reducing fragmentation. At the same time, several use cases have recently transitioned into execution, including Molecular Tumor Board (MTB), Pathogen Genomics, and Pharmacovigilance and Risk Management, demonstrating the ongoing commitment of the diverse CodeX community. Regular participation in HL7 FHIR Connectathons further validates interoperability across systems and stakeholders, reinforcing the scalability of these approaches.
CodeX is addressing some of the most persistent operational challenges in healthcare. Prior authorization is a significant source of administrative burden and delays in cancer treatment. Through its Prior Authorization in Medical Oncology use case, CodeX is advancing FHIR-based approaches to standardize and streamline these workflows. This work is informed by engagement from oncologists and administrators, including participation in a recent series of focus groups. In “Automating Prior Authorization in Medical Oncology with FHIR Standards: What CodeX Heard from Oncologists and Administrators,” we share insights on the complexity of current-state workflows and the opportunity to reduce friction, improve efficiency, and accelerate time to treatment through interoperability. This work demonstrates how CodeX grounds standards development in real-world clinical experience to drive meaningful, scalable change.
Underlying this progress is the mCODE standard, built on HL7 FHIR, that provides a consistent, structured framework for oncology data. By enabling a “collect once, use everywhere” model, mCODE supports more efficient data exchange, reduces duplication, and enhances the ability to leverage real-world data across care delivery and research. Building on its adoption to date, CodeX is also exploring opportunities to extend mCODE’s applicability internationally, including how it can be leveraged and adapted to support oncology data standardization in Europe and globally.
As CodeX continues to mature, its focus remains on scaling adoption and demonstrating impact. Through completed use cases, execution-ready implementations, and leadership in industry conversations such as genomics and data liquidity, CodeX is helping to define what effective, real-world interoperability looks like. Visit our CodeX calendar for upcoming community calls or reach out to pmo@hl7codex.org for more information.
